


Art Unit: 1700

CLM-PTO

April 21, 2005

Claims 1-24 are canceled.

25. A compound represented by C:



wherein



p is 1, 2, or 3;

W represents CH₂, O, or NR;

X represents S or O;

Y represents CR¹, or N;

R represents H or alkyl;

R¹ represents H, alkyl, or halogen;R₁ represents H or alkyl;R₂ represents aryl, or heteroaryl;R₃ represents H or alkyl;R₄ represents H or alkyl;R₅ represents H or alkyl;R₁ and R₂ may be connected through a covalent bond;R₃ and R₄ may be connected through a covalent bond;

R₂ and R₃ may be connected through a covalent bond; or -N(R₄)(R₅) represents 4-morpholinyl; and

the stereochemical configuration at a stereocenter in a compound represented by C is R, S, or a mixture thereof.

Art Unit: 1700

26. The compound of claim 25, wherein X represents S.
27. The compound of claim 25, wherein Y represents CR'.
28. The compound of claim 25, wherein W represents CH₂ or O.
29. The compound of claim 25, wherein n is 1 or 2; and p is 2.
30. The compound of claim 25, wherein R' represents H.
31. The compound of claim 25, wherein R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, or 5-chlorobenzo[b]thiophen-3-yl.
32. The compound of claim 25, wherein X represents S; and Y represents CR'.
33. The compound of claim 25, wherein X represents S; Y represents CR'; and W represents CH₂ or O.
34. The compound of claim 25, wherein X represents S; Y represents CR'; W represents CH₂ or O; n is 1 or 2; and p is 2.
35. The compound of claim 25, wherein X represents S; Y represents CR'; W represents CH₂ or O; n is 1 or 2; p is 2; and R' represents H.
36. The compound of claim 25, wherein X represents S; Y represents CR'; W represents CH₂ or O; n is 1 or 2; p is 2; R' represents H; and R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, or 5-chlorobenzo[b]thiophen-3-yl.

Claims 37-44 are canceled.

Art Unit: 1700

45. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC_{50} less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
46. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC_{50} less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
47. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC_{50} less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
48. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC_{50} less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
49. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC_{50} less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
50. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC_{50} less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
51. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC_{50} less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
52. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC_{50} less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
53. The compound of claim 1, 17, 25, or 37, wherein said compound has an IC_{50} less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
54. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC_{50} less than 1 μM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
55. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC_{50} less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

Art Unit: 1700

- 55. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC_{50} less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
- 56. The compound of claim 1, 17, 25, or 37, wherein said compound has an EC_{50} less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
- 57. The compound of claim 1, 17, 25, or 37, wherein said compound is a single stereoisomer.
- 58. A formulation, comprising a compound of claim 1, 17, 25, or 37; and a pharmaceutically acceptable excipient.

Claims 59-106 are canceled.